Resistance to loop diuretics. Why it happens and what to do about it.
Resistance to loop diuretics is often encountered clinically. Studies in healthy subjects have shown that overall response to loop diuretics depends upon the interplay between the total amount of drug reaching the urine, the time course of its entry into urine and the pharmacodynamics of response to diuretic in the urine. The mechanism by which diuretic resistance occurs has been elucidated in several clinical conditions. Treatment with inhibitors of prostaglandin synthesis has no effect on diuretic appearance in urine but blunts response by blocking the increase in renal blood flow produced by loop diuretics. In the elderly and in patients with moderate renal insufficiency, the mechanism of resistance appears to be purely pharmacokinetic, involving altered access of diuretic into the urine. In contrast, patients with nephrotic syndrome and hepatic cirrhosis manifest a purely pharmacodynamic form of resistance: in nephrosis, diuretic may bind to protein in the urine; in cirrhosis the mechanism of resistance is unclear. Lastly, in patients with congestive heart failure, with intravenous administration, resistance represents a pharmacodynamic phenomenon. With oral administration, however, the time course but not the extent of absorption is altered; consequently, in this setting, both pharmacokinetic and pharmacodynamic changes may contribute to the subnormal response. Strategies for overcoming resistance to loop diuretics in patients receiving NSAIDs or those with renal disease, hepatic cirrhosis or congestive heart failure include one or more of: increasing the dose size; administering frequent 'small' (but effective) doses; continuous intravenous infusion of the diuretic; or concomitant administration of another diuretic such as metolazone or hydrochlorothiazide.
D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D004039:Diet, Sodium-Restricted; D004232:Diuretics / Q000627:therapeutic use*; D004347:Drug Interactions; D004351:Drug Resistance; D005665:Furosemide / Q000627:therapeutic use / Q000652:urine; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000188:drug therapy; D008138:Loop of Henle / Q000187:drug effects; D009404:Nephrotic Syndrome / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D004232:Diuretics; D005665:Furosemide